Equities research analysts forecast that Jaguar Health Inc (NASDAQ:JAGX) will post earnings per share (EPS) of ($0.25) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Jaguar Health’s earnings. Jaguar Health posted earnings per share of ($42.66) in the same quarter last year, which indicates a positive year-over-year growth rate of 99.4%. The company is scheduled to report its next quarterly earnings results on Monday, November 18th.
On average, analysts expect that Jaguar Health will report full-year earnings of ($5.31) per share for the current fiscal year, with EPS estimates ranging from ($5.49) to ($5.12). For the next financial year, analysts forecast that the business will post earnings of ($1.30) per share, with EPS estimates ranging from ($2.39) to ($0.70). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Jaguar Health.
Jaguar Health (NASDAQ:JAGX) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($9.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.61) by ($3.48). The company had revenue of $1.71 million during the quarter, compared to analyst estimates of $3.05 million. Jaguar Health had a negative net margin of 727.27% and a negative return on equity of 698.61%.
Several analysts recently commented on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Jaguar Health in a research note on Thursday, September 12th. They set a “buy” rating and a $5.00 target price for the company. Zacks Investment Research raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a research note on Tuesday, October 22nd. Finally, ValuEngine raised shares of Jaguar Health from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd.
Shares of Jaguar Health stock traded down $0.03 during trading on Wednesday, reaching $0.74. The company had a trading volume of 286,200 shares, compared to its average volume of 492,870. The firm’s fifty day moving average is $0.91 and its 200-day moving average is $1.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.24 and a current ratio of 0.35. The company has a market cap of $37.09 million, a price-to-earnings ratio of 0.00 and a beta of 0.71. Jaguar Health has a fifty-two week low of $0.64 and a fifty-two week high of $37.10.
An institutional investor recently bought a new position in Jaguar Health stock. Wedbush Securities Inc. purchased a new stake in Jaguar Health Inc (NASDAQ:JAGX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 25,100 shares of the biotechnology company’s stock, valued at approximately $33,000. Wedbush Securities Inc. owned approximately 0.05% of Jaguar Health as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 0.11% of the company’s stock.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Featured Article: Lock-Up Period Expiration
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.